What it is
LL-37 is a human cathelicidin peptide studied for innate immunity, wound repair, and antimicrobial signaling.
Evidence boundary
Investigational / limited human evidence.
Trial evidence
- PMID 41544412 — LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review.
- PMID 41940199 — Mapping the landscape of antimicrobial peptides in periodontology: A scoping review.
- PMID 34068275 — Immunomodulatory Expression of Cathelicidins Peptides in Pulp Inflammation and Regeneration: An Update.
- PMID 42304678 — Crosstalk Between Probiotics and Host Immunity: Antimicrobial Peptides-Mediated Health Benefits.
Preparation and measurement
Reconstitution: 5 mg vial + 3 mL BAC = 1.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Week 1 (titration) | 50 mcg | 3 U (0.03 mL) | Once daily | 350 mcg/week |
| Week 2 | 100 mcg | 6 U (0.06 mL) | Once daily | 700 mcg/week |
| Week 3 | 150 mcg | 9 U (0.09 mL) | Once daily | 1.05 mg/week |
| Week 4 | 200 mcg | 12 U (0.12 mL) | Once daily | 1.4 mg/week |
| Weeks 5–8 (target) | 300 mcg | 18 U (0.18 mL) | Once daily | 2.1 mg/week |
Week 1 (titration)
- Dose
- 50 mcg
- Draw / measure
- 3 U (0.03 mL)
- Frequency
- Once daily
- Weekly total
- 350 mcg/week
Week 2
- Dose
- 100 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Once daily
- Weekly total
- 700 mcg/week
Week 3
- Dose
- 150 mcg
- Draw / measure
- 9 U (0.09 mL)
- Frequency
- Once daily
- Weekly total
- 1.05 mg/week
Week 4
- Dose
- 200 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Once daily
- Weekly total
- 1.4 mg/week
Weeks 5–8 (target)
- Dose
- 300 mcg
- Draw / measure
- 18 U (0.18 mL)
- Frequency
- Once daily
- Weekly total
- 2.1 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Light (100 mcg/day): Conservative dose.
-
Standard (250 mcg/day): Common research dose.
-
Higher (500 mcg/day): Acute infection / wound research.
-
Cycle: 2–4 weeks acute, 8–12 weeks chronic biofilm.
-
Wound response
-
Tolerability
-
Injection-site reactions
Practical rules
- Rotate sites if it is being compared in notes.
- Don’t let the antimicrobial language get broader than the source trail.
Related protocols
Thymosin Alpha-1 Peptide Protocol & DosingKPV Peptide Protocol & DosingBPC-157 Peptide Protocol & DosingARA-290 Peptide Protocol & DosingPNC-27 Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for LL-37 Peptide Protocol & Dosing are tracked with the current supplier listings.
View availability & COA →